The fact that HDAC4 and MAP2K7 are expressed at high levels suggests that the cancer-promoting effects of MAP2K7 in glioma cells could be stopped using drugs that inhibit HDAC4. The gene discussed is HDAC4; the disease is central nervous system cancer.